These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 18318758)

  • 21. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
    Bremnes RM; Sirera R; Camps C
    Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late relapse in patients with diffuse large B-cell lymphoma.
    Vose JM; Weisenburger DD; Loberiza FR; Arevalo A; Bast M; Armitage J; Bierman PJ; Bociek RG; Armitage JO
    Br J Haematol; 2010 Nov; 151(4):354-8. PubMed ID: 20880118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group.
    Shiozawa E; Takimoto M; Makino R; Adachi D; Saito B; Yamochi-Onizuka T; Yamochi T; Shimozuma J; Maeda T; Kohno Y; Kawakami K; Nakamaki T; Tomoyasu S; Shiokawa A; Ota H
    Leuk Res; 2006 Jul; 30(7):859-67. PubMed ID: 16406514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
    Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of clonal diversity of immunoglobulin gene rearrangements in patients with diffuse large B-cell lymphoma.
    Yang MH; Yen CC; Chiang SC; Bai LY; Lee KD; Hsiao LT; Chao TC; Wang WS; Liu JH; Chiou TJ; Chen PM
    Oncol Rep; 2005 Mar; 13(3):503-8. PubMed ID: 15706425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma.
    Nacinović-Duletić A; Stifter S; Dvornik S; Skunca Z; Jonjić N
    Int J Lab Hematol; 2008 Jun; 30(3):230-9. PubMed ID: 18479302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
    Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
    Kim SJ; Lee SJ; Sung HJ; Choi IK; Choi CW; Kim BS; Kim JS; Yu W; Hwang HS; Kim IS
    Acta Haematol; 2008; 120(4):211-6. PubMed ID: 19153476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
    Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
    Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum miR-146a and miR-223 as potential new biomarkers for sepsis.
    Wang JF; Yu ML; Yu G; Bian JJ; Deng XM; Wan XJ; Zhu KM
    Biochem Biophys Res Commun; 2010 Mar; 394(1):184-8. PubMed ID: 20188071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.
    Ng EK; Chong WW; Jin H; Lam EK; Shin VY; Yu J; Poon TC; Ng SS; Sung JJ
    Gut; 2009 Oct; 58(10):1375-81. PubMed ID: 19201770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.